Biora Therapeutics Announces New Patents for Targeted Therapeutics Platform
19 mai 2022 09h00 HE
|
Biora Therapeutics, Inc.
SAN DIEGO, May 19, 2022 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutics, today announced a new patent related to its Drug Delivery...
Biora Therapeutics to Participate in Upcoming H.C. Wainwright Global Investment Conference
16 mai 2022 16h30 HE
|
Biora Therapeutics, Inc.
SAN DIEGO, May 16, 2022 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutics, today announced that the Company’s management team will be...
Biora Therapeutics Provides Corporate Update and Reports First Quarter 2022 Financial Results
10 mai 2022 16h01 HE
|
Biora Therapeutics, Inc.
Completed transformation with the launch of Biora Therapeutics to reflect the company’s focus on oral therapeutic solutions Successfully transferred its single-molecule detection platform with...
Progenity Announces Successful Transfer of Liquid Biopsy Technologies
05 mai 2022 06h30 HE
|
Progenity, Inc.
SAN DIEGO, May 05, 2022 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG) today announced it has completed the divesture of a collection of novel, discovery-stage biochemical and bioinformatics...
Progenity to Report First Quarter Financial Results and Provide Corporate Update as Biora Therapeutics, Inc.
03 mai 2022 09h00 HE
|
Progenity, Inc.
SAN DIEGO, May 03, 2022 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG) today announced that it will report first quarter ended March 31, 2022 financial results on Tuesday, May 10, 2022 after the...
Progenity Appoints Paul Shabram to Lead Technical Operations of the Company’s Ingestible Drug/Device Platforms
25 avr. 2022 09h00 HE
|
Progenity, Inc.
SAN DIEGO, April 25, 2022 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), a biotechnology company innovating in the field of oral biotherapeutics for gastrointestinal health and beyond, today...
Progenity to Become Biora Therapeutics as it Completes Transformation
12 avr. 2022 09h00 HE
|
Progenity, Inc.
SAN DIEGO, April 12, 2022 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), a biotechnology company innovating in the field of oral biotherapeutics for gastrointestinal health and beyond, today...
Progenity Announces Two Poster Presentations at Controlled Release Society 2022
06 avr. 2022 09h00 HE
|
Progenity, Inc.
SAN DIEGO, April 06, 2022 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), a biotechnology company innovating in the field of oral biotherapeutics for gastrointestinal health and beyond, today...
Progenity Provides Corporate Update and Reports Fourth Quarter and Full Year 2021 Financial Results
28 mars 2022 16h01 HE
|
Progenity, Inc.
Accelerated Company Transformation Toward Oral Delivery of Biotherapeutics and Targeted Therapeutics Programs Progressed Company’s Targeted Therapeutics Clinical Programs with Initiation of Clinical...
Progenity to Report Fourth Quarter and Full-Year 2021 Financial Results and Provide Corporate Update
16 mars 2022 16h23 HE
|
Progenity, Inc.
SAN DIEGO, March 16, 2022 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), a biotechnology company innovating in the field of oral biotherapeutics for gastrointestinal health and beyond, today...